S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
3rd Massive Dollar Upheaval Has Started (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
3rd Massive Dollar Upheaval Has Started (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
3rd Massive Dollar Upheaval Has Started (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
3rd Massive Dollar Upheaval Has Started (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
NASDAQ:NVAX

Novavax - NVAX Stock Forecast, Price & News

$57.25
-3.02 (-5.01%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$56.84
$62.75
50-Day Range
$36.28
$76.12
52-Week Range
$34.88
$277.80
Volume
5.50 million shs
Average Volume
6.00 million shs
Market Capitalization
$4.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$162.57

Novavax MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
184.0% Upside
$162.57 Price Target
Short Interest
Healthy
19.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
0.00mentions of Novavax in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-61.00%
From $27.23 to $10.62 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

391st out of 1,293 stocks

Biological Products, Except Diagnostic Industry

64th out of 197 stocks

NVAX stock logo

About Novavax (NASDAQ:NVAX) Stock

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Price Performance

Novavax stock traded down $3.02 during trading hours on Monday, hitting $57.25. The company had a trading volume of 5,502,091 shares, compared to its average volume of 6,004,275. The firm has a market cap of $4.47 billion, a PE ratio of -3.24, a PEG ratio of 0.06 and a beta of 1.52. Novavax has a one year low of $34.88 and a one year high of $277.80. The firm has a 50-day moving average of $53.79 and a 200 day moving average of $63.64.

Novavax (NASDAQ:NVAX - Get Rating) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.33 by ($0.77). The business had revenue of $703.97 million for the quarter, compared to analyst estimates of $845.20 million. Novavax had a negative return on equity of 572.54% and a negative net margin of 93.91%. The business's revenue for the quarter was up 57.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($3.05) EPS. As a group, research analysts expect that Novavax will post 27.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald boosted their price target on shares of Novavax from $146.00 to $168.00 in a report on Wednesday, June 8th. Cowen reaffirmed a "buy" rating and issued a $150.00 target price on shares of Novavax in a research note on Friday, June 3rd. Bank of America started coverage on shares of Novavax in a research note on Friday, May 20th. They issued an "underperform" rating and a $35.00 target price for the company. Finally, B. Riley reduced their target price on shares of Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Novavax currently has a consensus rating of "Hold" and an average price target of $162.57.

Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Stock News Headlines

Is it Time to Cash Out Novavax Stock?
Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S.
He's Giving Away His Ultimate Dividend Package FOR FREE!
Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free. pixel
Why Novavax Stock Got Mashed on Monday
He's Giving Away His Ultimate Dividend Package FOR FREE!
Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free. pixel
Why Novavax Stock Jumped on Tuesday
B. Riley Lowers Novavax (NASDAQ:NVAX) Price Target to $171.00
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Company Calendar

Last Earnings
11/04/2021
Today
8/08/2022
Next Earnings (Confirmed)
8/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,541
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$162.57
High Stock Price Forecast
$209.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+184.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-1,743,750,000.00
Pretax Margin
-91.86%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Book Value
($4.65) per share

Miscellaneous

Free Float
76,494,000
Market Cap
$4.47 billion
Optionable
Optionable
Beta
1.52

Social Links


Key Executives

  • Mr. Stanley Charles Erck (Age 74)
    Pres, CEO & Director
    Comp: $1.12M
  • Mr. James Patrick Kelly C.F.A. (Age 56)
    Exec. VP, CFO & Treasurer
    Comp: $355.23k
  • Mr. John A. Herrmann III (Age 56)
    Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $657.8k
  • Mr. John Joseph Trizzino B.S. (Age 62)
    M.B.A., Exec. VP and Chief Bus. & Commercial Officer
    Comp: $636.85k
  • Dr. Gregory M. Glenn (Age 68)
    Pres of R&D
    Comp: $813.44k
  • Mr. Richard P. Crowley (Age 65)
    Exec. VP & COO
  • Dr. Gale E. Smith (Age 72)
    Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist
  • Mr. Biegie Lee
    Sr. VP & Chief Information Officer
  • Ms. Silvia Taylor M.B.A.
    MBA, Sr. VP of Global Corp. Affairs & Investor Relations
  • Mr. Troy Morgan Esq. (Age 51)
    J.D., Sr. VP & Chief Compliance Officer













NVAX Stock - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVAX shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price forecast for 2022?

8 Wall Street analysts have issued 12-month price objectives for Novavax's stock. Their NVAX share price forecasts range from $35.00 to $209.00. On average, they anticipate the company's stock price to reach $162.57 in the next twelve months. This suggests a possible upside of 184.0% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How has Novavax's stock price performed in 2022?

Novavax's stock was trading at $143.07 at the beginning of 2022. Since then, NVAX stock has decreased by 60.0% and is now trading at $57.25.
View the best growth stocks for 2022 here
.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our NVAX earnings forecast
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.31) earnings per share for the quarter, missing the consensus estimate of ($4.04) by $0.27. The biopharmaceutical company earned $178.80 million during the quarter, compared to the consensus estimate of $347.34 million. Novavax had a negative net margin of 93.91% and a negative trailing twelve-month return on equity of 572.54%. The firm's quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($3.21) EPS.

When did Novavax's stock split?

Novavax shares reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by a number of retail and institutional investors. Top institutional investors include IMC Chicago LLC (0.00%), Candriam S.C.A. (0.17%), Van ECK Associates Corp (0.14%), Wolverine Asset Management LLC (0.00%), State Board of Administration of Florida Retirement System (0.11%) and Banco Bilbao Vizcaya Argentaria S.A. (0.09%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends
.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $57.25.

How much money does Novavax make?

Novavax (NASDAQ:NVAX) has a market capitalization of $4.47 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.68) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 1,541 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.